Help us determine the safety and efficacy of an experimental drug

Closed for Enrollment

Study Name
Biogen SOD1 Phase III Clinical Trial
Michael Benatar, MD, PhD
Study Type
Interventional (Clinical Trial), Phase III, Randomized, Placebo-controlled
Eligible Population
Individuals affected with ALS, and positive for an SOD1 gene mutation that is associated with rapidly progressive disease
Study Purpose/Goals

To determine the safety and efficacy of the experimental drug BIIB067 in patients with SOD1 ALS

40 weeks of participation

  • Screening: up to 4 weeks
  • Treatment: 32 weeks (9 doses, once every 2 weeks x 2 doses, then once every 4 weeks)
  • Follow-up: 4 weeks
  • Open label extension


  • Medical history and medication review
  • Drug dosing
  • Blood, urine and CSF collection
  • Neurological exam
  • Muscle testing
  • Electrocardiogram
  • Physical exam
  • Surveys
  • Breathing tests
  • Biomarker procedures (HHD, MUNIX)

Join our family - together, we can change the course of this disease.

Join our family

Together, we can change the course of this disease.

Copyright © 2020. ALS Center at the University of Miami. All Rights Reserved. Branding by Mok2